The ability to engineer primary human B cells to differentiate into long-lived plasma cells and secrete a de novo protein may allow the creation of novel plasma cell therapies for protein deficiency diseases and other clinical applications. We initially developed methods for efficient genome editing of primary B cells isolated from peripheral blood. By delivering CRISPR/Cas9 ribonucleoprotein (RNP) complexes under conditions of rapid B cell expansion, we achieved site-specific gene disruption at multiple loci in primary human B cells (with editing rates of up to 94%). We used this method to alter ex vivo plasma cell differentiation by disrupting developmental regulatory genes. Next, we co-delivered RNPs with either a single-stranded DNA oligonucleotide or adeno-associated viruses containing homologous repair templates. Using either delivery method, we achieved targeted sequence integration at high efficiency (up to 40%) via homology-directed repair. This method enabled us to engineer plasma cells to secrete factor IX (FIX) or B cell activating factor (BAFF) at high levels. Finally, we show that introduction of BAFF into plasma cells promotes their engraftment into immunodeficient mice. Our results highlight the utility of genome editing in studying human B cell biology and demonstrate a novel strategy for modifying human plasma cells to secrete therapeutic proteins.

INTRODUCTION

Long-lived plasma cells stably reside in the bone marrow for decades and secrete large quantities of antibodies. Consequently, plasma cells engineered to produce de novo proteins have the potential to be curative therapies for protein deficiency diseases, prophylaxis for infectious diseases, and many other applications. However, the development of plasma cell therapeutics has been limited by technical challenges in the in vitro modification, culture, expansion, and differentiation of primary human B cells. B cells can be transduced at high rates by recombinant adeno-virus or Epstein-Barr virus (EBV) vectors, which deliver transgenes as episomes. However, episomal DNA expression is lost over time, limiting use of these vectors in applications that require long-term transgene expression. Unlike non-integrating vectors, gamma retrovirus (γRV) and lentivirus (LV) randomly integrate into the host genome and can be used to introduce stably expressing transgenes. However, these vectors are inefficient at transducing primary human B cells. LVs that employ alternative envelopes, including that of baboon retrovirus, measles virus, or gibbon-ape leukemia virus, exhibit higher B cell transduction rates (up to ~50%) but have low viral titers, which make large-scale production challenging. Because γRV and LV vectors do not efficiently transduce B cells, whereas transduction by non-integrating vectors results in only transient transgene expression, neither platform is currently effective for delivering long-term expression of exogenous genes to B cells on a therapeutic scale.

An alternative method for introducing stable protein expression is genome editing via homology-directed repair (HDR). Following cleavage by an engineered site-specific nuclease, DNA double-strand breaks are resolved through non-homologous end joining (NHEJ), an error-prone DNA repair pathway that typically leads to variable insertions or deletions (indels), or HDR, which repairs DNA by copying a homologous donor template. Delivery of exogenous DNA flanked by DNA homologous to the genomic sequence around the break site can lead to incorporation of the exogenous sequence in a site-specific manner. HDR-mediated genome editing in B cells may have several advantages over viral vector transduction for therapeutic applications, including decreased risk of insertional mutagenesis and sustained transgene expression. We and others have recently achieved high-efficiency HDR delivery of therapeutic transgenes to hematopoietic cells, including primary human T cells and hematopoietic stem cells, but similar approaches are yet to be applied in the modification of primary human B cells.

King L. Hung,1 Iana Meitlis,1,3 Malika Hale,1,3 Chun-Yu Chen,1 Swati Singh,1 Shaun W. Jackson,1 Carol H. Miao,1 Iram F. Khan,1 David J. Rawlings,1,2 and Richard G. James1,2

1Center for Immunity and Immunotherapies, Seattle Children’s Research Institute, Seattle, Washington, USA; 2Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.

Received 22 August 2017; accepted 11 November 2017; https://doi.org/10.1016/j.ymthe.2017.11.012.

These authors contributed equally to this work.

Correspondence: Richard G. James, Seattle Children’s Research Institute, 1900 9th Ave, Seattle, WA 98195, USA.
E-mail: rickeri@u.washington.edu

Correspondence: David J. Rawlings, Seattle Children’s Research Institute, 1900 9th Ave, Seattle, WA 98195, USA.
E-mail: rawling@u.washington.edu

456 Molecular Therapy Vol. 26 No 2 February 2018 © 2017 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The CRISPR/Cas9 system is an RNA-guided nuclease platform that is easily engineered to efficiently target specific sites in the genome for cleavage, generating double-strand DNA breaks.13,14 The use of site-specific nucleases for gene disruption or HDR in B cells is currently limited to transformed or lymphoma-derived cell lines and murine models and has required plasmid- or LV-based CRISPR/Cas9 delivery.15 Here, we describe high-efficiency genome editing in human peripheral blood B cells (75%–90% gene disruption or 10%–40% HDR) by delivering CRISPR/Cas9 ribonucleaseprotein (RNP) complexes alone or in combination with single-stranded DNA oligonucleotide (ssODN) or adeno-associated virus (AAV) repair templates, respectively. We show that edited primary B cells can be subsequently differentiated in culture into plasma cells that produce physiological doses of therapeutic proteins, including human factor IX (FIX).

RESULTS

Optimized Conditions for Expansion of Primary Naive Human B Cells

Rapid cell cycling19 and/or persistence in the S/G2 phases of the cell cycle19,20 promote HDR in both cell lines and primary hematopoietic cells. Based on previous reports demonstrating rapid expansion of primary human B cells ex vivo, we initially used a combination of stimulants21–23 (hereafter called “B cell activation cocktail”) that included artificially oligomerized CD40 ligand (MEGACD40L; two linked CD40L trimers) in association with CpG, interleukin-2 (IL-2), IL-10, and IL-15. We isolated primary human CD19+ B cells from peripheral blood mononuclear cells (PBMCs) and cultured them for 13 days with this B cell activation cocktail. This treatment resulted in a ~36-fold expansion of B cells (Figure S1A) while preserving viability at >60% (Figure S1B). Most cells maintained a naive B cell phenotype (CD27+/CD138–/CD38low/CD19+CD38hi/CD19highIgM+IgD+). Finally, we found a ~65% knockdown. We isolated and cultured them for 5 additional days. Total genomic DNA was isolated on day 5 and target regions were PCR amplified and analyzed using the T7 endonuclease 1 (T7E1) assay (one representative experiment shown) or Illumina sequencing for percentages of on-target indels (112,000 reads per experimental condition). n represents the number of independent experiments. We used one-way ANOVA with the Sidak correction for multiple comparisons; ***p < 0.001; ns, not significant.

Figure 1. Cas9 RNP Induces Site-Specific Indels or a Precise Single Nucleotide Change in the Presence of an ssODN in Primary Human B Cells

(A) CD19+ B cells were isolated and activated in vitro for 2 days, mock treated or transfected with Cas9 RNPs targeting CCR5 or PRDM1 (CCR5g, PRDM1g-1, or PRDM1g-2), and cultured for 5 additional days. Total genomic DNA was isolated on day 5 and target regions were PCR amplified and analyzed using the T7 endonuclease 1 (T7E1) assay (one representative experiment shown) or Illumina sequencing for percentages of on-target indels (112,000 reads per experimental condition). (B) Diagram of wild-type PRDM1 locus, PRDM1g-2 target location, and the ssODN donor template containing a single nucleotide change. (C and D) B cells were activated for 2 days and mock treated and electroporated with Cas9 RNP-PRDM1g-2 alone or with the ssODN donor template at serially increasing doses from 7.5 pmol to 120 pmol. (C) Viabilities of B cells 2 days and 5 days after genome editing (n = 3, three donors). No significant difference in viability was observed between mock and up to 30 pmol ssODN plus RNP on either day 2 or day 5. Bar graph shows mean ± SEM. (D) Percentage of HDR, indel, and wild-type (WT) alleles in total genomic DNA extracted 5 days after genome editing as assessed by Illumina sequencing (greater than 1 million reads per experimental condition). n represents the number of independent experiments. We used one-way ANOVA with the Sidak correction for multiple comparisons; ***p < 0.001; ns, not significant.

To assess the efficiency of Cas9-mediated indels in B cells, we designed CRISPR guide RNAs that target CCR5 (which is not expressed in human B cells24 and has no known significance in plasma cell development) or PRDM1 (encoding BLIMP1, a protein required for B cell differentiation into plasma cells). After optimizing electroporation using mRNA (Figure S2), we transfected 30 pmol Cas9-guide RNP complexes into B cells, cultured them for 5 additional days under activating conditions, and extracted total genomic DNA to assess nuclease-induced indels using the T7 endonuclease 1 assay (Figure S1A). Illumina sequencing confirmed on-target indels and revealed that the RNP s induced high indel frequencies at each guide target site (43%–84%; Figure 1A). Western blot also verified concomitant PRDM1 protein reduction in the PRDM1-expressing TMD8 lymphoma cell line (Figure S3A; ~65% knockdown). Finally, we found that B cells remained viable despite these genome modifications (Figure S3B). These data show that high-efficiency Cas9-mediated gene disruption is achievable in primary human B cells.

Cas9-Mediated Disruption of CCR5 and PRDM1 in Primary Human B Cells

To assess the efficiency of Cas9-induced indels in B cells, we designed CRISPR guide RNAs that target CCR5 (which is not expressed in human B cells24 and has no known significance in plasma cell development) or PRDM1 (encoding BLIMP1, a protein required for B cell differentiation into plasma cells). After optimizing electroporation using mRNA (Figure S2), we transfected 30 pmol Cas9-guide RNP complexes into B cells, cultured them for 5 additional days under activating conditions, and extracted total genomic DNA to assess nuclease-induced indels using the T7 endonuclease 1 assay (Figure S1A). Illumina sequencing confirmed on-target indels and revealed that the RNP s induced high indel frequencies at each guide target site (43%–84%; Figure 1A). Western blot also verified concomitant PRDM1 protein reduction in the PRDM1-expressing TMD8 lymphoma cell line (Figure S3A; ~65% knockdown). Finally, we found that B cells remained viable despite these genome modifications (Figure S3B). These data show that high-efficiency Cas9-mediated gene disruption is achievable in primary human B cells.

HDR-Mediated Single Nucleotide Substitution at the PRDM1 Locus Using an ssODN Donor Template

Cas9-induced DNA lesions can be seamlessly repaired via the HDR pathway in the presence of a donor template with homology
sequences flanking the lesion. We initially tested an ssODN as a donor template based on promising results in other cell types. We designed a 120-base ssODN containing asymmetric homology arms flanking the PRDM1g-2 target site, with a single nucleotide change at the 90th position that mutates the last nucleotide of the protospacer adjacent motif (PAM) (GGG to GGT; Figure 1B). This single nucleotide change was designed to both prevent Cas9-mediated cleavage of the repaired sequence and serve as a molecular marker for HDR. In this experiment, primary human B cells were activated for 2 days and then transfected with Cas9 RNP in conjunction with various doses of the ssODN. 2 and 5 days following transfection, cells transfected with ≤30 pmol ssODN had comparable viabilities to Cas9 RNP-transfected control cells (Figure 1C). In cells receiving 15 or 30 pmol ssODN, sequencing of the PRDM1 target region on day 5 post-transfection revealed 20%–22% of alleles had undergone HDR, whereas another 37%–41% had indels (Figure 1D), an overall editing rate that was marginally higher than that observed in the Cas9 RNP control (Figure 1D). Thus, ssODN donor templates can be used to achieve high rates of HDR in primary human B cells, with low cytoxicity.

Cas9-Mediated Disruption of Genes That Regulate Plasma Cell Development

We next investigated whether Cas9-induced gene disruption can be used to study gene roles in human plasma cell development and antibody production. To do so, we developed an experimental workflow that includes inducing NHEJ-mediated gene disruption in activated naïve human B cells using Cas9 RNPs and subsequently differentiating naïve B cells into plasma cells (CD19lowCD38highCD27+) using a three-step plasma cell culture system (see Figure 2A, the Materials and Methods section, and previous description for detailed conditions). As a proof of concept, we studied four genes encoding transcription factors previously reported to regulate plasma cell development in murine studies: IRF4 and PRDM1/BLIMP1 are known to inhibit naive B cells to become plasma cells, whereas PAX5 and BACH2 antagonize plasma cell differentiation in vitro.

We designed CRISPR guides targeting each of these four genes, transfected primary B cells with Cas9 RNP targeting each gene independently, and subsequently induced in vitro plasma cell differentiation (Figure 2A). As a control, we also transfected cells with Cas9 RNPs targeting CCR5. Following differentiation, we detected significantly lower percentages of CD19lowCD38high CD27+CD138+ plasma cells in cultures transfected with PRDM1- or IRF4-targeting RNPs compared to cells transfected with CCR5-targeting RNP or mock transfected cells (mean indel percentages = 89%, 83%, and 92% at the PRDM1, IRF4, and CCR5 target sites, respectively; Figures 2C and 2D). Because antibody secretion is a major function of plasma cells, we measured IgM and IgG levels in cell culture supernatants by ELISA and found IgG to be significantly decreased in the PRDM1- and IRF4-targeted B cell cultures (Figure 2E). Together, as predicted, these data imply that both PRDM1 and IRF4 are required for human plasma cell differentiation and antibody production. Conversely, we observed significant increases in the percentages of plasma cells in cultures transfected with either PAX5- or BACH2-targeting RNPs (mean indel percentages = 80% and 86% at the PAX5 and BACH2 target sites, respectively; Figures 2C and 2D). We also observed concomitant increases in IgM and IgG secretion in PAX5-targeted cultures (Figure 2E). Again, as predicted, these data indicate that Cas9-mediated disruption of PAX5 or BACH2 enhances human plasma cell differentiation. Further, the IgG/IgM ratio in BACH2-targeted B cell cultures was markedly lower than in mock or CCR5-targeted cultures (Figures 2E and S4A) and plasmablasts in PAX5-targeted cultures exhibited decreased surface CD19 expression (Figure S4B), both consistent with previous studies in mice. Finally, we confirmed that independent guide RNAs targeting the same genes lead to similar alterations in plasma cell differentiation (Figure S4C). Taken together, these results demonstrate that CRISPR/Cas9-induced gene disruption in primary B cells is useful for interrogating gene products that may modulate human plasma cell development and function.

Site-Specific HDR at the PRDM1 Locus Using Co-delivery of RNP and AAV Donor Template

HDR using ssODN donor templates is not suitable for delivering payloads larger than ~400 bases due to current limitations of the fidelity of ssODN synthesis. In contrast, AAV can package up to ~4.7 kb of the ssDNA donor template. We and others have used AAV to deliver candidate HDR templates, leading to high levels of HDR in multiple cell types and at a variety of loci. Of note, there are no published data regarding the capacity of AAV to transduce primary human B cells. To investigate AAV transduction efficiency in human B cells, we designed a self-complementary AAV (scAAV) with a GFP coding sequence driven by MND, a robust retroviral-derived ubiquitous promoter. We transduced activated B cells with this vector, which was packaged using various serotypes, and quantified GFP expression 2 days post transduction by flow cytometry. Regardless of serotype, we observed minimal loss of cell viability following viral exposure (Figure S5A). We observed the highest percentage of GFP+ cells (mean = 43%) and highest mean fluorescence intensity in B cells transduced with AAV serotype 6 (Figure 3A).

Because the packaging size of single-stranded AAV (ssAAV) is greater than that of scAAV, we next assessed the efficacy of HDR-mediated integration of larger payloads by delivering ssAAV and Cas9 into B cells. Initially, we designed an AAV6 donor template containing an MND-driven GFP cassette flanked by 400-bp homology arms at the PRDM1g-2 target site (PRDM1-GFP; Figure 3B). The PAM was not included in the repair template, thereby rendering the repaired sequence non-cleaveable by Cas9 (Figure 3B). After activation and electroporation with or without Cas9 RNP, B cells were transduced with AAV6 PRDM1-GFP at various MOIs and cultured for 11 additional days with the same activating factors. Although we initially observed a 30% viability loss at the highest AAV dose, these cultures eventually recovered and exhibited comparable viabilities by day 11 (Figure S5B). At the highest AAV MOI, we observed persistent GFP expression in ~10% of cells that received both the PRDM1-targeting RNP and AAV repair template, whereas 2% of cells that were treated with AAV alone had persistent GFP expression.
In addition, we co-treated cells with the PRDM1-targeting RNP and a non-targeting AAV BFP control (MND-BFP without homology arms; BFP-noHA) and observed ~1% BFP expression at the endpoint (Figure 3C), indicating that the majority of GFP expression resulting from co-delivery of PRDM1-targeting RNP and PRDM1-GFP was likely driven by HDR-mediated integration.
also found that higher AAV doses correlated with increased percentages of GFP+ cells. Finally, we found that increasing homology arm lengths from 400 bp to 1.0 kb did not lead to higher levels of HDR (measured as persistent GFP expression; Figures S6A and S6B).

Together, these data support the conclusion that co-delivery of Cas9 RNP and AAV can lead to efficient, targeted genomic integration of transgene, likely via the HDR pathway.

Generation of Active FIX-Secreting Human Plasma Cells via HDR-Mediated Integration at the CCR5 Locus

Engineering exogenous protein production in plasma cells may have therapeutic applications in protein deficiency diseases such as hemophilia B, which is caused by a deficiency of FIX. To assess whether primary B cells could be engineered to secrete active proteins with predicted functionality, we used an HDR-mediated knockin strategy to engineer de novo expression of FIX. Of note, our HDR studies targeting the PRDM1 locus (described above) were anticipated to under-represent HDR efficiencies due to the negative impact of PRDM1 disruption on plasma B cell differentiation and the relative inefficiency of the guide used in the studies (PRDM1g-2; Figure 1A). Therefore, we targeted the CCR5 locus as a “safe harbor” because (1) it is not transcriptionally active in human B cells; (2) it is not required for plasma cell differentiation (Figures 2A–2D); and (3) heterozygous and homozygous null mutations in CCR5 are innocuous to human carriers. To generate plasma B cells capable of secreting exogenous human FIX, we co-delivered an AAV vector containing an MND-driven FIX (codon-optimized FIX-R338L Padua variant) expression cassette, with the same flanking CCR5 homology arms as described above (CCR5-FIX), into primary human B cells with or without CCR5-targeting RNP (Figure 4A). To boost plasma cell differentiation in these cultures, we also co-delivered PAX5-targeting RNPs in a subset of CCR5-targeted cells. Although we observed similar HDR rates of ~15%–20% at the CCR5 locus across conditions (Figure 4B), following plasma cell differentiation, we observed increases in CD19lowCD38high plasmablast percentages in the cultures that received both CCR5- and PAX5-targeting RNPs (Figure 4A).

To assess whether the FIX produced by gene-edited plasma cells is active, we supplemented cultures with vitamin K1 to enable...
vitamin-K-dependent post-translational carboxylation of FIX and subsequently measured FIX activity levels using a chromogenic assay. We found that FIX activity was significantly higher in the vitamin-K1-supplemented, gene-edited plasma cell cultures (Figure 4E). The observed low level of activity in the BFP-noHA negative controls was absent when fetal bovine serum (FBS) was removed from cultures, suggesting that this non-specific assay background originates from FIX present in FBS. Importantly, FIX produced by gene-edited plasma cells exhibited high specific activity (50 IU/mg protein) in a vitamin-K-dependent manner (Figure 4F). These data demonstrate production of functional FIX via targeted HDR in gene-edited human B cells using Cas9 RNP and AAV and illustrate the possibility of multi-locus modifications to simultaneously drive plasma cell differentiation and de novo protein secretion.

Engineered BAFF Secretion via HDR Improves Plasma Cell Survival In Vitro

In order to use gene-edited plasma cells in a therapeutic setting, their long-term survival will be required. One strategy to improve plasma cell survival is to engineer cells that secrete survival factors in an autocrine manner. As a first test of this approach, we used our HDR-mediated knockin strategy to engineer de novo expression of the
B cell activating factor (BAFF). We designed two AAV6 repair templates: one contained MND-driven GFP and BAFF linked with a T2A self-cleaving peptide (CCR5-GFP-BAFF) and the other contained only an MND-BAFF expression cassette (CCR5-BAFF). Both donor constructs contained 800-bp homology arms around the CCR5 guide target site (Figure 5A). Following RNP transfection and/or AAV transduction, we cultured cells using the three-step plasma cell culture system (Figure 2A). As in earlier PRDM1-targeting experiments, we observed persistent GFP expression (mean = 33% GFP+) only in the condition containing both CCR5-targeting RNP and AAV (Figures 5B and S7). Regardless of the template used, we observed similar rates of HDR as quantified by digital PCR (~28%–31% HDR; Figure 5C). Although use of both donor templates led to BAFF secretion, B cells targeted by CCR5-BAFF (repair template solely containing BAFF) exhibited much higher levels of BAFF secretion (4.1-fold increase) relative to those targeted by CCR5-GFP-BAFF (template containing BAFF downstream of the T2A linkage) (Figure 5D). To determine if this exogenous BAFF is functional, we assessed cell expansion and plasmablast formation following genome editing and in vitro differentiation. In the CCR5-BAFF edited culture that contained the highest concentration of exogenous BAFF, we observed increases in cell number, viability, and percentage of CD19lowCD38high plasmablasts relative to controls that lacked Cas9 RNP (Figures 5E and S7). This is consistent with previous studies showing that BAFF promotes both human and murine B cell survival and differentiation. Taken together, these results show that Cas9 RNP- and AAV-mediated genome editing can be used to generate functional, BAFF-secreting human plasma cells with improved in vitro survival.

BAFF-Expression Human Plasma Cells Exhibit Sustained Secretory Capabilities in NSG Mice

We next tested whether autocrine BAFF secretion might promote plasma cell survival in vivo in immunodeficient NOD/SCID/gamma-c null (NSG) mice. We first generated gene-edited B cells using co-delivery of CCR5-targeting RNP and the CCR5-GFP-BAFF AAV donor template. Edited cells were differentiated into plasma cells in vitro using the three-step culture system and adoptively transferred into NSG mice via intravenous infusion (Figure 6A). In parallel, we transferred equal numbers of unedited plasma cells into a separate cohort of NSG recipients and also evaluated control unmanipulated animals. Serum samples were collected at days 10 and 21, and human protein was quantified by ELISA (Figure 6A). As expected, human BAFF was detected only in mice that received BAFF-expressing cells (Figure 6B). Human IgM and IgG were detected only in mice that received edited or unedited human plasma cells and not in control mice (Figure 6C). Notably, serum BAFF and IgM levels remained stable from day 10 to day 21 and human IgG levels progressively increased during this period only in recipients of BAFF-expressing edited plasma cells (Figures 6B and 6C). Most strikingly, we observed significantly higher levels of IgM and IgG in mice that received BAFF-expressing plasma cells (Figure 6C; difference in IgG levels at day 10 was not significant). These findings demonstrate that gene-modified plasma cells can maintain stable secretory capacities in vivo for at least 3 weeks and support our hypothesis that expression of a human-relevant survival factor via genome editing can promote plasma cell secretory function and/or survival in vivo.

DISCUSSION

Here, we report high rates of gene disruption in primary human B cells at multiple loci using CRISPR/Cas9 RNPs. We apply this method to modeling the impact of genetic changes on human plasma cell differentiation. We also demonstrate the use of Cas9 RNP in combination with ssODN or AAV6 repair templates to achieve high-efficiency HDR in B cells and engineer secretion of functional and therapeutically relevant proteins. Importantly, gene-modified cells obtained a plasma cell phenotype following 13 days of culture (including 2 days pre-editing) in vitro and are detectable in humanized mice for at least 3 weeks, suggesting the potential for the future development of adoptive cell therapies using engineered human plasma cells.

Cas9-mediated disruption of PRDM1, IRF4, PAX5, or BACH2, which either promote (PRDM1 and IRF4) or inhibit (PAX5 and BACH2) plasma cell differentiation in mice, led to human B cell phenotypes consistent with these regulatory roles. The ability to easily disrupt genes or induce single-base changes using Cas9 RNP with or without ssODN-mediated HDR will likely facilitate further study of the impact of genetic changes on human B cell development. When combined with differentiation in vitro, this system could be used as a high-throughput model for studying genetic mutations that alter human B cell development, including somatic and/or germ-line mutations associated with a range of human B cell disorders (in B cell lymphoma and in autoimmune disorders, including systemic lupus erythematosus). It will enable a range of mechanistic studies designed to assess candidate genes identified by genome-wide association studies.

Our development of a method for the efficient, site-specific introduction of transgenes via HDR opens the possibility of engineering plasma cells to act as autologous “cell factories” capable of delivering sustained, high doses of therapeutic proteins to patients. As a proof of concept, we engineered plasma cells to secrete FIX. Deficiency of FIX is the cause of hemophilia B, a genetic disease characterized by blood clotting defects. Current treatment for hemophilia B is limited to protein replacement therapy, which is costly and non-curative. Recent gene therapy trials reported long-term FIX expression in patients after intravenous injection of a liver-tropic AAV8-FIX vector; however, pre-existing AAV-neutralizing antibodies to all known AAV serotypes are prevalent in humans and greatly limit in vivo AAV transduction, making a significant group of patients with anti-AAV antibodies ineligible for treatment. In addition, systemic AAV delivery induces humoral immunity against AAV that prevents subsequent delivery, thus limiting AAV therapy to a single dose and/or necessitating use of alternative serotypes. Delivery of ex vivo gene-edited plasma cells producing FIX would remove the requirement for systemic AAV delivery and likely avoid limitations posed by AAV-neutralizing antibodies.
Figure 5. HDR-Mediated Integration of BAFF Coding Sequence at the CCR5 Locus Results in Persistent BAFF Secretion by Gene-Edited Plasma Cells and Increases Plasma Cell Differentiation and Viability

(A) Schematic of wild-type CCR5 locus, CCR5g target location, an AAV construct that co-expresses GFP and BAFF via T2A linkage (AAV CCR5-GFP-BAFF), and a BAFF-expressing AAV construct (AAV CCR5-BAFF) with identical 800-bp flanking CCR5 homology arms. (B–F) B cells were gene edited after 2 days of in vitro activation, and were subsequently differentiated into plasma cells using the three-step culture system. (B) Upper: representative flow plots showing GFP expression on day 2 and day 11 post gene editing in mock, CCR5-GFP-BAFF transduced cells, with or without Cas9 RNP. Lower: bar graph summarizing percentages of GFP+ cells on day 2 and day 11 post gene editing (n = 4, three donors). (C) Frequency of on-target donor template integration in total alleles on day 11 after genome editing as assessed by digital droplet PCR (n = 3, two donors). (D) Bar graph shows BAFF production as measured by ELISA at day 11 (n = 4, three donors). (E) Left: cells were counted at day 5 and day 11 post genome editing. Bar graph shows fold changes in cell numbers. Right: viabilities at day 11 by flow cytometry (n = 5, four donors). (F) Left: representative flow plots showing CD19 and CD38 expression at day 11 after genome editing using the AAV CCR5-BAFF vector. Right: bar graph summarizing percentages of CD19lowCD38high plasmablasts/plasma cells at day 11 (n = 5, four donors). Both AAV CCR5-GFP-BAFF and CCR5-BAFF were added at 20,000 MOI. All bar graphs show mean ± SEM. n represents the number of independent experiments. We used one-way ANOVA with the Sidak correction for multiple comparisons; **p < 0.01; ***p < 0.001. HA, homology arm; IL-2ss, IL-2 signal sequence; pA, SV40 poly-adenylation signal; PAM, protospacer adjacent motif; WT, wild-type.
In addition, immune responses to therapeutic proteins comprise a key unaddressed challenge. Based on evidence that B cell delivery can induce tolerance, an additional application of B cell editing technology would be to deliver smaller numbers of short-lived B cells producing FIX, or other relevant immunogenic proteins, with the goal of inducing tolerance to the secreted product. This approach would be useful alone as well as in a setting in which it might be paired with co-delivery of gene-edited plasma cells, producing a therapeutic protein anticipated to provoke an unwelcome immune response.

In this proof of principle study, we have only begun to assess the in vivo stability, homing, and safety of engineered plasma cells. Our engraftment studies contrast with the majority of those previously reported using human cells in NSG and other immunodeficient murine models in that we have attempted to transplant mature cells into adult mice. In most other successful studies, human stem cells have been engrafted into humanized murine models, at times including co-engraftment with human fetal liver or thymus into neonatal animals. In these cases, CD34+ stem cells can differentiate into B cells and even mature B cells. However, the majority of the engrafted cells remain in the transitional and/or immature developmental stages. In particular, development of PCs post-immune challenge has met with very limited success and can be increased by the provision of additional human cytokines. Consistent with these ideas, our demonstration that engineering mature B cells to express human BAFF can confer engraftment advantage parallels studies showing that access to human cytokines, including IL-6, SIRPA, or T cell factors, promote B cell maturation and the ability to respond to immunization in mice. Radruch and colleagues have shown that it is possible to transfer mature murine plasma B cells into immune-deficient mice and that these cells can home to the spleen and bone marrow and stably produce functional antibody for at least 21 weeks. For us to perform similar studies using human mature plasma cells, we will need to determine the key human growth or survival factors that promote and maintain a human plasma cell niche in murine models.

One important question is how many engrafted engineered plasma cells will be required to deliver therapeutic levels of an exogenous protein like FIX. Based on a study that quantified serum antibody levels and the number of antigen-specific plasma cells in immunized mice, a single antibody-secreting plasma cell can stably maintain ~50 ng serum IgG. In patients with severe hemophilia B, 3% (or 30 IU/L) of persistent FIX is considered therapeutic, which roughly translates into ~2.5 mg FIX per adult subject (based on 5 L blood). Consequently, if we were able to deliver a plasma cell that produced FIX at the same rate as an anti-tetanus secreting plasma cell, we would require ~50,000 engineered cells to deliver a therapeutic dose. The present rate of production in our plasma cell cultures is considerably lower than that of an anti-tetanus antibody-secreting cell: ~1–10 pg/edited cell per day. Therefore, given our current protein production levels, we would require engraftment of a much larger number of edited cells to reach therapeutic levels of FIX. However, we anticipate that simple changes to our methods, including elimination of competing secreted antibody, use of a plasma cell locus, and enrichment for edited plasma cells will substantially increase protein production per gene-edited cell and, therefore, the translational potential for this approach.

In summary, our study demonstrates high rates of locus-specific genome editing in primary human B cells. These engineered B cells retain the ability to differentiate into plasma cells ex vivo and secrete physiological doses of therapeutic proteins such as FIX. The ability to efficiently target specific loci enables us to drive B cell differentiation and secretory programs. Thus, creative multiplexing of gene disruption and HDR will likely provide ever more powerful tools to coordinately optimize protein secretion, cellular phenotype, and long-term survival.
MATERIALS AND METHODS

CRISPR/Cas9 Reagents and ssODNs
CRISPR RNAs (crRNAs) targeting the CCR5, PRDM1, IRF4, PAX5, and BACH2 loci (sequences in Table S1) were identified using the MIT CRISPR design tool (http://crispr.mit.edu/) and the Broad Institute single guide RNA (sgRNA) design tool (http://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design) and synthesized (IDT) containing phosphorothioate linkages and 2′O-methyl modifications. ssODNs were commercially synthesized by IDT (Ultramer DNA Oligonucleotides) with phosphorothioate linkages. crRNA and trans-activating crRNA (tracrRNA; IDT) hybrids were mixed with Cas9 nuclease (IDT) at a 1:2:1 ratio and delivered with or without ssODNs to cells by Neon electroporation (Thermo Fisher Scientific).

Production of Recombinant AAV Vectors
AAV stocks were produced as previously described.34 The AAV vector, serotype helper, and HgT1-adenov helper plasmids were transfected into HEK293T cells. Cells were harvested 48 hr later and lysed by 3 freeze-thaw cycles, and the cell lysate was treated with benzonase. Virions with recombinant AAV genomes were purified using an iodixanol density gradient. All MOI calculations were based on qPCR-based titers of AAV genomes using inverted terminal repeat (ITR)-specific primers and probe.55 Details of the individual vectors are available in the Supplemental Materials and Methods.

Samples and Primary Human B Cell Genome Editing
PBMCs were collected from whole blood of consented donors and cryopreserved at the Fred Hutchinson Cancer Research Center. CD19+ B cells were subsequently isolated by negative selection (Pan-B cell kit, Miltenyi Biotec) and cultured in Iscove’s modified Dulbecco’s medium (IMDM) (Thermo Fisher Scientific) supplemented with 10% FBS and 55 μM beta-mercaptoethanol at 1 × 10^6 cell/mL to 1.5 × 10^6 cells/mL. B cells were activated with 100 ng/mL recombinant human MEGACD40L (Enzo Life Sciences), 1 ng/mL CpG oligodeoxynucleotide 2006 (Invitrogen), 50 ng/mL IL-2 (PeproTech), 50 ng/mL IL-10 (PeproTech), and 10 ng/mL IL-15 (PeproTech) for 2 days. Cells were then electroporated with Cas9 RNP complexes (see Supplemental Materials and Methods).

Flow Cytometry
Flow cytometric analysis was done on an LSR II flow cytometer (BD Biosciences) and data were analyzed using FlowJo software (Tree Star). Flow cytometry gating for fluorescent proteins (Figure S8A), viability (Figure S8B), and immunophenotyping (Figure S8C) are described in the Supplemental Materials and Methods.

Plasma Cell Differentiation Culture
Plasma cells were differentiated in vitro using a three-step culture system as previously described.27 CD19+ B cells were activated and gene edited as outlined above and expanded for 5 days in the same cocktail. Following washing with 1X PBS, the cells were seeded in medium with IL-2 (50 ng/mL), IL-6 (50 ng/mL), IL-10 (50 ng/mL), and IL-15 (10 ng/mL) for 3 days. Next, the cells were washed with 1X PBS and seeded in medium with IL-6 (50 ng/mL), IL-15 (10 ng/mL), and human interferon-γ 2B (15 ng/mL, Sigma-Aldrich) for 3 days to stimulate plasma cell differentiation.

ELISA
3 days prior to measuring culture protein levels, cells were collected, washed with PBS, and then resuspended in new culture medium at 1 × 10^6 cells/mL. After 3 days, the culture supernatant was collected and protein secretion levels were determined by ELISA for IgG and IgM (Ready-SET-Go, eBioscience, San Diego, CA), BAFF (BAFF/BLyS/Quantikine ELISA Kit, R&D Systems, Minneapolis, MN), and FIX (FIX Human ELISA Kit, Abcam, Cambridge, MA).

FIX Chromogenic Assay
Activity of recombinant FIX expressed by gene-edited B cells was assessed using a chromogenic assay (Rox Factor IX, 900020). The procedure was performed following the manufacturer’s instructions. Absorbance values were measured using a VICTOR3 plate reader (PerkinElmer). A human normal pooled plasma standard was used to establish the calibration curve.

To assess FIX activity in edited plasma cell cultures, B cells were edited and differentiated in vitro. At day 8 post genome editing, FBS content was reduced from 10% to 2% of culture to reduce assay background. Insulin, transferrin, and sodium selenite (Thermo Fisher Scientific) were added to cultures to maintain cell survival in the reduced FBS environment. Finally, in specified cultures that were supplemented with vitamin K1 (Sigma-Aldrich), 5 μg/mL vitamin K1 was added to the medium for generating active FIX via vitamin-K-dependent carboxylation. 0.005% was used to increase solubility of vitamin K1.

NSG Mouse Transplant
NSG mice were purchased from Jackson Laboratory and maintained in a designated pathogen-free facility at the Seattle Children’s Research Institute (SCRI). All animal studies were performed according to the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) standards and were approved by the SCRI Institutional Animal Care and Use Committee (IACUC).

In our NSG transplant experiment, NSG mice were conditioned with 25 mg/kg Busulfan (Selleckchem) via intraperitoneal injection. 24 hr after conditioning, 10 × 10^6 in vitro differentiated plasma B cells, either mock or edited BAFF expressing, were delivered into each 6- to 8-week-old NSG recipient via retro-orbital infusion. Mice were bled at day 10 and sacrificed at day 21 post infusion. All peripheral blood samples were collected in serum separator tubes for serum collection.

Statistical Analysis and Data Availability
Statistical analyses were performed using GraphPad Prism 7 (GraphPad, San Diego, CA). Because there wasn’t obvious skewing in any of the conditions and there was minimal variation within
conditions, we assumed all data followed a normal distribution. 
p values in multiple comparisons were calculated using one-way
ANOVA with the Sidak correction; p values in comparisons between
two groups were calculated using a paired two-tailed t test. Values
from independent experiments are shown as mean ± SEM. The acces-
sion number for all sequencing data is NCBI Sequence Read Archive:
SRP113557.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Materials and
Methods, nine figures, and two tables and can be found with this
article online at https://doi.org/10.1016/j.ymthe.2017.11.012.

AUTHOR CONTRIBUTIONS
R.G.J. and D.J.R. conceived the project. I.F.K., R.G.J., and D.J.R.
directed the studies. K.L.H., I.M., M.H., I.F.K., and R.G.J. per-
formed the experiments and analyzed the molecular and phenotypic
data generated in the gene editing experiments. C.-Y.C. and C.H.M.
provided assistance/advice and performed some analysis of the factor
IX expression studies. K.L.H. and S.S. performed and analyzed the
in vivo humanized mouse studies. S.W.J. gave important feedback
regarding B cell culture and differentiation conditions. K.L.H.,
D.J.R., and R.G.J. wrote the paper. All authors edited and
approved the manuscript.

CONFLICTS OF INTEREST
The authors declare that they have nothing to disclose.

ACKNOWLEDGMENTS
We thank Karen Sommer for reading the manuscript and providing
helpful comments. We thank Eric Allenspach for help with flow-cy-
tometry-based phenotyping in the B cell development experiments.
We thank Integrated DNA Technologies for sharing reagents not
used in the final submitted manuscript. We thank Lea Starita and
Josh Cuperus for assistance with the deep sequencing analysis. This
work was supported by the Seattle Children’s Research Institute,
Center for Immunity and Immunotherapies, Seattle Children’s Research
Institute Program for Cell and Gene Therapy, Children’s Guild Asso-
ciation Endowed Chair in Pediatric Immunology (to D.J.R.),
and NIDDK and NCI of the NIH under awards DP3DK111802-01 (to
D.J.R. and R.G.J.) and R01CA201135-01A1 (to R.G.J.).

REFERENCES
1. Radbruch, A., Muehlberg, G., Lugner, E.O., Inamine, A., Smith, K.G., Dorner, T.,
and Hiepe, F. (2006). Competence and competition: the challenge of becoming a
long-lived plasma cell. Nat. Rev. Immunol. 6, 741–750.
2. Slifka, M.K., Antia, R., Whitmire, J.K., and Ahmed, R. (1998). Humoral immunity
due to long-lived plasma cells. Immunity 8, 363–372.
3. Kim, E.K., Seo, H.S., Chae, M.I., Jeon, I.S., Song, B.Y., Park, Y.J., Ahn, H.M., Yun,
C.O., and Kang, C.Y. (2014). Enhanced antitumor immunotherapeutic effect of
B-cell-based vaccine transduced with modified adenoviral vector containing type
35 fiber structures. Gene Ther. 21, 106–114.
4. Hellebrand, E., Mautner, J., Reischab, G., Nimmerjahn, F., Hallek, M., Mocikat, R.,
and Hammerschmidt, W. (2006). Epstein-Barr virus vector-mediated gene transfer
into human B cells: potential for antitumor vaccination. Gene Ther. 13, 150–162.
5. Frecha, C., Costa, C., Lévy, C., Négre, D., Russell, S.J., Maisner, A., Salles, G., Peng,
K.W., Gosset, F.L., and Verhoeven, E. (2009). Efficient and stable transduction of
resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles
virus gp displaying lentiviral vectors. Blood 114, 3173–3180.
6. Serafini, M., Naldini, L., and Introna, M. (2004). Molecular evidence of inefficient
transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1-
derived lentivectors. Virology 325, 413–424.
7. Lévy, C., Fusi, F., Amirache, F., Costa, C., Girard-Gagnepain, A., Négre, D., Bernadin,
O., Garaulet, G., Rodriguez, A., Nair, N., et al. (2016). Baboon envelope pseudotyped
lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell
secretion in vivo in NOD/SCIDγ−/− mice. J. Thromb. Haemost. 14, 2478–2492.
8. Lévy, C., Amirache, F., Costa, C., Frecha, C., Muller, C.P., Kweyer, H., Buckland, R.,
Gosset, F.L., and Verhoeven, E. (2012). Lentiviral vectors displaying modified measles
virus gp overcome pre-existing immunity in in vivo-like transduction of human
T and B cells. Mol. Ther. 20, 1699–1712.
9. Mock, U., Thiele, R., Uhde, A., Felse, B., and Horn, S. (2012). Efficient lentiviral
transduction and transgene expression in primary human B cells. Hum. Gene
Ther. Methods 23, 408–415.
10. Hale, M., Mesojednik, T., Romano Ibarra, G.S., Sahni, J., Bernard, A., Sommer, K.,
Scharenberg, A.O., Rawlings, D.J., and Wagner, T.A. (2017). Engineering HIV-resis-
tant, anti-HIV chimeric antigen receptor T cells. Mol. Ther. 25, 570–579.
11. Dever, D.P., Bak, A.O., Reinsch, A., Camarena, J., Washington, G., Nicolaus, C.E.,
Pavel-Dinu, M., Saxena, N., Wilkens, A.B., Mantri, S., et al. (2016). CRISPR/Cas9
β-globin gene targeting in human haematopoietic stem cells. Nature 539, 384–389.
12. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F.,
Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of
CCR5 in primary human hematopoietic cells using a megatAL nuclease and AAV
donor template. Sci. Transl. Med. 7, 307ra156.
13. Mali, P., Yang, L., Esville, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and
Church, G.M. (2013). RNA-guided human genome engineering via Cas9. Science
339, 823–826.
14. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang,
W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using
CRISPR/Cas systems. Science 339, 819–823.
15. Chu, V.T., Graf, R., Wirtz, T., Weber, T., Favret, J., Li, X., Petsch, K., Tran, N.T.,
Sieweke, M.H., Berek, C., et al. (2016). Efficient CRISPR/Cas9-mediated mutagenesis in
primary immune cells using CrispRicheld and a C57BL/6 Cas9 transgenic mouse
line. Proc. Natl. Acad. Sci. USA 113, 12514–12519.
16. Pogson, M., Parola, C., Kelton, W.J., Heuberger, P., and Reddy, S.T. (2016).
Immunogenetic engineering of a plgK-and-display hybridoma platform. Nat.
Commun. 7, 12535.
17. Choeung, T.C., Compagno, M., and Chiarle, R. (2016). Editing of mouse and human
immunoglobulin genes by CRISPR-Cas9 system. Nat. Commun. 7, 10934.
18. Gwiazda, K.S., Grier, A.E., Sahni, J., Burleigh, S.M., Martin, U., Yang, J.G., Popp,
N.A., Krutein, M.C., Khan, I.F., Jacoby, K., et al. (2016). High efficiency CRISPR/Cas9-
mediated gene editing in primary human T-cells using mutant adenoviral E4orf6/8
helper structures. J. Immunol. 196, 1540–1549.
19. Lin, S., Staahl, B.T., Alla, R.K., and Doudna, J.A. (2014). Enhanced homology-
directed human genome engineering by controlled timing of CRISPR/Cas9 delivery.
eLife 3, e04766.
20. Heyer, W.D., Ehmsen, K.T., and Liu, J. (2010). Regulation of homologous recombi-
ation in eukaryotes. Annu. Rev. Genet. 44, 113–139.
21. Jiang, W., Lederman, M.M., Harding, C.V., Rodriguez, B., Mohner, R.J., and Sieg, S.F.
(2007). TL98 stimulation drives naïve B cells to proliferate and to attain enhanced
antigen presenting function. Eur. J. Immunol. 37, 2205–2213.
22. Armitage, R.J., Macduff, B.M., Eisenman, J., Paxton, R., and Grabstein, K.H. (1995).
IL-15 has stimulatory activity for the induction of B cell proliferation and differenti-
ation. J. Immunol. 154, 483–490.
23. Armitage, R.J., Macduff, B.M., Spriggs, M.K., and Fanslow, W.C. (1993). Human B
cell proliferation and Ig secretion induced by recombinant CD40 ligand are modu-
lated by soluble cytokines. J. Immunol. 150, 3671–3680.
24. Rottman, J.B., Ganley, K.P., Williams, K., Wu, L., Mackay, C.R., and Ringler, D.J. (1997). Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am. J. Pathol. 151, 1341–1351.

25. Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308.

26. Richardson, C.D., Ray, G.J., DeWitt, M.A., Curie, G.L., and Corn, J.E. (2016). Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat. Biotechnol. 34, 339–344.

27. Jourdan, M., Caraux, A., De Vos, J., Fiol, G., Larroque, M., Cognot, C., Bret, C., Dupeyray, C., Hose, D., and Klein, B. (2009). An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114, 5173–5181.

28. Ochiai, K., Maineschein-Cliner, M., Simonetti, G., Chen, J., Rosenthal, B., Brink, R., Chong, A.S., Klein, U., Dietter, A.R., Singh, H., and Sciammas, R. (2013). Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity 38, 918–929.

29. Shaffer, A.L., Lin, K.I., Kuo, T.C., Yu, X., Hirt, E.M., Rosenwald, A., Gilliance, J.M., Yang, L., Zhao, H., Calame, K., and Staadt, L. (2002). Blimp1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17, 51–62.

30. Muto, A., Ochiai, K., Kimura, Y., Itoh-Nakadai, A., Calame, K.L., Ikebe, D., Tashiro, S., and Igarashi, K. (2010). Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J. 29, 4048–4061.

31. Nera, K.P., Kohonen, P., Narvi, E., Mustonen, L., Terho, P., Koskela, K., Buerstedde, J.M., and Lasila, O. (2006). Loss of Pax5 promotes plasma cell differentiation. Immunity 24, 283–293.

32. Muto, A., Tashiro, N., Nakajima, O., Hoshino, H., Takahashi, S., Sakoda, E., Ikebe, D., Yamamoto, M., and Igarashi, K. (2004). The transcriptional programme of antibody class switching involves the repressor Bach2. Nature 429, 566–571.

33. Koizum, Z., Wang, S., Dorfler, P., Adams, B., and Buslunger, M. (1992). The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol. Cell. Biol. 12, 2662–2672.

34. Khan, I.F., Hirata, R.K., and Russell, D.W. (2011). AAV-mediated gene targeting and molecular characterization. Nat. Protoc. 6, 482–501.

35. Hirata, R., Chamberlain, J., De Vos, J., Fiel, G., Larroque, M., Cognot, C., Bret, C., Duperray, C., Hose, D., and Klein, B. (2009). An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114, 5173–5181.

36. Russell, D.W., and Hirata, R.K. (1998). Human gene targeting by viral vectors. Nat. Biotechnol. 16, 748–755.

37. Challita, P.M., Skelton, D., el-Khoueiry, A., Yu, X.J., Weinberg, K., and Kohn, D.B. (1995). Multiple modalities for gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 85, 4865–4870.

38. Melo, M.E., Qian, J., El-Amine, M., Agarwal, R.K., Soukhareva, N., Kang, Y., and Scott, D.W. (2002). Gene transfer of Ig fusion proteins into B cells prevents and treats autoimmune diseases. J. Immunol. 168, 4788–4797.

39. Yu, H., Borsotti, C., Schickel, J.N., Zhu, S., Struewig, T., Eynon, E.E., Feleti, D., Gurer, C., Murphy, A.J., Yanopoulos, G.D., et al. (2017). A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood 129, 959–969.

40. Wiley, L.A., Schotte, R., Legrand, N., and Spits, H. (2014). Critical assessment of human antibody generation in humanized mouse models. J. Immunol. Methods 410, 18–27.

41. Chen, Q., Ke, F., Kwang, J., Chan, J.K., and Chen, J. (2012). GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation. J. Immunol. 188, 2523–2529.

42. Lang, J., Kelly, M., Freed, B.M., McCarter, M.D., Kedl, R.M., Torres, R.M., and Pelanda, R. (2013). Studies of lymphocyte reconstitution in a humanized mouse model reveal a requirement of T cells for human B cell maturation. J. Immunol. 190, 2090–2101.

43. Cheng, Q., Mumtaz, I.M., Khodadadi, L., Radbruch, A., Hoyer, B.F., and Hiepe, F. (2013). Autoantibodies from long-lived ‘memory’ plasma cells of NZB/W mice drive immune complex nephritis. Ann. Rheum. Dis. 72, 2011–2017.

44. Manz, R.A., Thiel, A., and Radbruch, A. (1997). Lifetime of plasma cells in the bone marrow. Nature 388, 133–134.

45. Aurnhammer, C., Haase, M., Muether, N., Hausl, M., Rauschhuber, C., Huber, I., Nitschlo, H., Busch, U., Sing, A., Ehrhardt, A., and Baiker, A. (2012). Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18–28.